What is Eloralintide?
Eloralintide is an investigational selective amylin receptor agonist developed for weight-management research. It is pharmacologically distinct from GLP-1 receptor agonists, even though both are studied in metabolic disease.
Mechanism & research focus
Its target is amylin-receptor signaling, a hormone pathway associated with regulation of food intake and nutrient responses. Receptor selectivity is a property of the characterized investigational molecule and needs independent confirmation for any research material.
What the research covers
A 2025 randomized phase 2 trial enrolled 263 adults with overweight or obesity without type 2 diabetes. Over 48 weeks, eloralintide groups had greater mean weight reduction than placebo. Nausea and fatigue were among the most common adverse events.
What remains uncertain
This study does not establish efficacy in every population, long-term cardiovascular outcomes or complete safety. Comparisons with separate trials of other agents cannot demonstrate superiority. A commercial vial bearing the same name is not verified as equivalent to the controlled clinical product.
The evidence label describes the linked research, not the suitability of a catalog product for use in people. Formulation, identity, purity, and measured content must be assessed separately.
Sources & studies
Eloralintide for obesity: a 48-week randomized phase 2 trial ↗
Multicentre placebo-controlled trial with 263 participants; registered as NCT06230523.
Read the full paper for its design, controls and limitations. A source link is not a claim that its tested material matches a DA formulation.
Catalog formats & documentation
Formats grouped by compound identity. Availability and batch documentation remain on Disguised Alpha.
Original DA reference: Eloralintide research guide ↗